Important announcements from the Hong Kong stock market today:
1) Company News
$WUXI APPTEC (02359.HK)$Continued to sell the held through block trades.$WUXI XDC (02268.HK)$50.8 million shares of Stocks, accounting for approximately 4.23% of WUXI XDC's current total share capital, with a transaction amount of approximately 2.178 billion Hong Kong dollars and an investment return of approximately 1.847 billion yuan.
The announcement states that the cash revenues obtained from this sale will be used to accelerate the advancement of Global production capacity and capability construction, attract and retain outstanding talent, and continuously strengthen the company's unique integrated CRDMO business model.
$TRISTATE HOLD (00458.HK)$An affiliate, Hefei Uni-Asia, has entered into a construction contract with contractor Anhui Fuhuang Steel Structure Co., Ltd., under which the contractor will provide services to build logistics facilities on the land according to the terms and conditions of the construction contract, for a contract amount of 45.1396 million yuan.
$CHINA POWER (02380.HK)$An affiliate, Haiwei Wind Power, has signed a general contracting agreement with ShanDong Institute, under which the latter will provide surveying design, equipment procurement, construction installation works, and other technical support services for the transmission line project, at a cost of 61.509 million yuan.
$ESSEX BIO-TECH (01061.HK)$The phase III clinical study results of the anti-VEGF ophthalmic injectable biological drug for treating wet AMD patients in China have reached the primary research endpoint.
$HENLIUS (02696.HK)$The phase III clinical study of the recombinant anti-VEGF humanized monoclonal antibody injection HLX04-O for the treatment of wet age-related macular degeneration (wAMD) has reached the primary research endpoint.
2) Financing and repurchase dynamics
$BABA-W (09988.HK)$: In the first quarter, a total of 51 million shares of common stock were repurchased at a total price of 0.6 billion USD, all conducted in the USA market as per the repurchase plan; as of March 31, 2025, there is still a repurchase quota of 20.1 billion USD authorized by the Board of Directors under the share repurchase plan, valid until March 2027.
$CSTONE PHARMA-B (02616.HK)$: It is proposed to place a total of 80 million placement shares, accounting for about 5.86% of the expanded issued share capital after placement. The placement price is 2.933 HKD per placement share, with the estimated net proceeds amounting to 0.232 billion HKD, 90% of which will be used for assets in the group's 'Pipeline 2.0'.
$TENCENT (00700.HK)$: 0.5 billion HKD was used to repurchase 0.996 million shares, with repurchase prices ranging from 499.4 HKD to 508 HKD.
$HSBC HOLDINGS (00005.HK)$: 0.142 billion HKD was spent to repurchase 1.6 million shares, with repurchase prices between 88.15 HKD and 89.1 HKD.
Editor/rice